NLS Pharmaceutics AG: NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies

Related Keywords

Switzerland ,United States ,Miami ,Florida ,Swiss ,American ,Eric Konofal ,European Medicines Agency ,Company Contacts ,Exchange Commission ,Pharmaceutics Ltd ,American Society Of Clinical Psychopharmacology ,Nasdaq ,American Society ,Clinical Psychopharmacology ,Chief Scientific Officer ,Nocturnal Activity ,Orexinb Saporin Induced Narcoleptic Like Model ,Dependent Response ,Activity Monitoring ,Orphan Disease Designation ,Mazindol Controlled Release ,Orphan Drug Designations ,Ihr Portfolio ,